Nasopharyngeal carcinoma – treatment possibilities in patients with primary metastatic carcinoma

• Authors: Marek Kowalczyk , Michał Piątek , Dorota Imielska-Zdunek , Aleksandra Derra , Aleksandra Zemła , Agnieszka Boratyn-Nowicka
• Languages of publication: EN

Abstracts

EN

This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies (chemotherapy, targeted therapy, radiotherapy), and includes a case report. The applied treatment allowed for satisfactory control of the disease and much higher overall survival than expected – the patient survived for 53 months from the initial diagnosis and 41 months from being diagnosed with metastatic carcinoma.

Keywords

EN

nasopharyngeal carcinoma; strategy of treatment; systemic therapy

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2017
• Volume: 7
• Issue: 1
• Pages: 44-48

Contributors

author

Marek Kowalczyk

• Clinical Oncology Department, UCK Katowice, Poland

author

Michał Piątek

• Clinical Oncology Department, UCK Katowice, Poland

author

Dorota Imielska-Zdunek

• Radiotherapy Department, UCK Katowice, Poland

author

Aleksandra Derra

• Medical University of Silesia, Poland

author

Aleksandra Zemła

• Medical University of Silesia, Poland

author

Agnieszka Boratyn-Nowicka

• Clinical Oncology Department, UCK Katowice, Poland

References

• 1. Fandi A, Atum M, Azli N et al. Nasopharyngeal cancer epidemiology, staging, and treatment. Semin Oncol 1994; 21: 382-397.
• 2. Bień S, Kawecki A, Krajewski A, Starościak S. Zasady diagnostyki i chirurgicznego leczenia nowotworów głowy i szyi. Magazyn Otorynolaryngologiczny 2002; 1(13): 23-29.
• 3. Dubrulle F, Souillard R, Hermans R. Extension patterns of nasopharyngeal carcinoma Eur Radiol 2007; 10: 2622-2630.
• 4. A bdulamir AS, Hafidh RR, Abdulmuhaimen N et al. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. BMC Public Health 2008; 8: 400. doi: 101186/1471-2458-8-400.
• 5. Barnes L, Eveson J, Reichart P, Sidransky D. Pathology and genetics of head and neck tumors. World Health Organization Classification of Tumours 2005.
• 6. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15(10): 1765-1777.
• 7. Tian YM, Zeng L, Wang FH et al. Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis a retrospective study for the management of treatment. Radiation Oncol 2013; 8: 272.
• 8. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma a study of 256 male patients. J Surg Oncol 1986; 33(3): 194-197.
• 9. Ma BB, Tannock IF, Pond GR et al. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002; 95: 2516-2523.
• 10. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008 GLO BOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
• 11. Curado M, Edwards B, Shin H et al. Cancer incidence in five continents. IARC scientific publications 2007: 160.
• 12. Teo PM, Kwan WH, Lee WY et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996; 77(12): 2423-2431.
• 13. Onga YK, Heng DM Heng YK et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 2003; 39: 1535-1541.
• 14. Hildesheim A, West S, DeVeyra E et al. Herbal medicine use, Epstein-Barr virus, and risk of nasopharyngeal carcinoma. Cancer Res 1992; 52(11): 3048-3051.
• 15. Yu MC. Nasopharyngeal carcinoma epidemiology and dietary factors. IARC Sci Publ 1991; 105: 39-47.
• 16. Zheng YM, Tuppin P, Hubert A et al. Environmental and dietary risk factors for nasopharyngeal carcinoma a case-control study in Zangwu County, Guangxi, China. Br J Cancer 1994; 69(3): 508-514.
• 17. Mabuchi K, Bross DS, Kessler II. Cigarette smoking and nasopharyngeal carcinoma. Cancer 1985; 55: 2874-2876.
• 18. Lee AW, Poon YF , Foo W et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985 overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23: 261-270.
• 19. Chan ATC, Grégoire V, Lefebvre JL et al. Nasopharyngeal cancer EHNS–ES9MO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (supl 7): 83-85.
• 20. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol 2012; 22(3): 233-244.
• 21. Ali H, al-Sarraf M. Chemotherapy in advanced nasopharyngeal cancer. Oncology 2000; 14(8): 1223-1230. (discussion 1232-1227, 1239-1242).
• 22. Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma current and future directions. Cancer Sci 2008; 99(7): 1311-1318.
• 23. Merlano M, Occelli M. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag 2007; 3(5): 871-876.
• 24. Chan ATC, Hsu MM, Goh BC et al. Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. J Clin Oncol 2005; 23 (15): 3568-3576.
• 25. Ma BB, Poon TC, To KF et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma. A prospective study. Head Neck 2003; 25: 864-872.
• 26. Bień S. Rola infekcji wirusem Epsteina i Barr w schorzeniach głowy i szyi. Polski Przegląd Otorynolaryngologiczny 2013; 2(3): 127-136.
• 27. 2014 Report on the State of the Art of Rare Diseases Activities in Europe – Part I. Overview of Rare Disease Activities in Europe – July 2014 [online: http://ec.europa.eu/health//sites/health/files/rare_diseases/docs/2014report_rare_disease_activitieseu_1_en.pdf]
• 28. Hilton Boon M, Ritchie K, Manson J. Improving the retrieval and dissemination of rare disease guidelines and research recommendations a RARE- Bestpractices initiative. Rare Diseases and Orphan Drugs 2014; 1: 20-29.

• Document Type: article